AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03239483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine gel
Description: Dapivirine gel (0.05%); administered rectally
Study NCT04475367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without App hypercross group
Description: Interdisciplinary health care
Study NCT01035086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fabricated food
Description: The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
Study NCT01035086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fabricated food
Description: The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
Study NCT03239483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Universal HEC placebo gel; administered rectally
Study NCT01949155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201
Description: Single, intratympanic injection
Study NCT01035086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fabricated food
Description: The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
Study NCT04785313 — intervention group
Intervention type: BIOLOGICAL
Intervention: Retrievable Inferior Vena Cava Filters (IVCF)
Description: Analysis anatomopathology of Retrievable Inferior Vena Cava Filters (IVCF) (ALN CF model).
Study NCT01949155 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Simulated single, intratympanic injection
Study NCT04785313 — intervention group
Intervention type: OTHER
Intervention: Demographics data collection
Description: Demographics data : age, gender, thromboembolic risk factors, Retrievable Inferior Vena Cava Filters (IVCF) (indication, dates of insertion and removal), and anticoagulant management during the period with filter.
Study NCT05379374 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine and morphine
Description: Bupivacaine group will receive 0.25% bupivacaine 20 ml in TAP block. Bupivacaine morphine group will receive 0.25% bupivacaine 20 ma with 3 mg morphine in TAP block.
Study NCT02523560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based telerehabilitation
Description: Patients qualified to the study group will undergo, at five medical units a 9-week program of early hybrid, comprehensive cardiac telerehabilitation.
Study NCT02887690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modular Prosthetic Limb
Study NCT03114007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventure program
Description: Personality-targeted interventions conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural components. They include real life 'scenarios' shared by local youth with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
Study NCT03114007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equipe program
Description: Parent training program designed to be delivered in community settings accessible to large groups of parents of 13 to 18 year olds. It uses a coping modeling problem solving process in which parents are the key players in developing problem solving strategies.~Parents participate in group workshops with themes related to communication, conflict resolution, cooperative transitions, negotiating, house rules, monitoring, consequences for serious problems and problem solving. Parents are guides to establish solutions to common problems. Readings and videotapes are used in the workshops to guide parents in identifying common challenges in child management, parenting errors, discussing possible consequences and alternative strategies as well as rationales supporting these strategies.
Study NCT03114007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inter-Action services
Description: An intervention model designed to provide integrated services for youth with significant symptoms of mental health problems, substance misuse and/or psychosocial difficulties. Young people with such difficulties will benefit from stepped and collaborative care involving interventions of varied intensity adapted to their needs and the severity of their problems. These will include cognitive behavioral therapy, motivational interviews, dialectic behavioral therapy and family interventions provided by multidisciplinary teams of professionals. A case navigator will be in charge of initiating service provision and ensuring a fast and smooth flow of information between indicated services providers.
Study NCT05703867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active microcurrent therapy
Description: Non-invasive transpalpebral microcurrent therapy delivery to the upper and lower eyelids
Study NCT05379374 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: bupivacaine and morphine
Description: Bupivacaine group will receive 0.25% bupivacaine 20 ml in TAP block. Bupivacaine morphine group will receive 0.25% bupivacaine 20 ma with 3 mg morphine in TAP block.
Study NCT02298582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal fentanyl
Description: During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
Study NCT04116424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse training of the patient
Description: visit + telephone follow-up
Study NCT04116424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neurologist accompaniement
Description: presentation during consultation by neurologist
Study NCT00418951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: 400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily
Study NCT00418951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Description: 3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes
Study NCT00418951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Description: 9 mg/kg intravenously once per week over 2 hours +/- 15 minutes
Study NCT05251623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking program
Description: Subjects in PG walked to target steps daily with pedometer for 6 weeks
Study NCT01260727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-G DNA Vaccine
Description: PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL
Study NCT01260727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR Vaccine
Description: MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10\^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume of 1 mL in either deltoid
Study NCT01260727 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PENNVAX-G Vaccine
Description: Sodium Chloride Injection USP, 0.9%
Study NCT01260727 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MVA-CMDR Vaccine
Description: Sodium Chloride Injection USP, 0.9%
Study NCT02367326 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: data collection will be carried out by the investigator during a standard hospitalization of the patient
Study NCT01219647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: subjects will participate in one of two forms of exercise
Study NCT01219647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stretching
Description: subjects will particiopate in supervised stretching as described in arm description.
Study NCT02018367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine, high resolution imaging
Description: 5-10mL of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the biopsy channel of the endoscope and gently placed against the mucosa. The endoscopist will image each discrete lesion observed during white light endoscopy. For each HRME imaged area, an optical read will be obtained followed by a tissue biopsy.
Study NCT04005651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POD L GF IOL
Description: Cataractous lens will be removed in the study eyes and the POD L GF IOL will be implanted in the capsular bag
Study NCT04005651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symfony® IOL
Description: Cataractous lens will be removed in the study eyes and the Symfony® IOL will be implanted in the capsular bag
Study NCT04005651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof® IOL
Description: Cataractous lens will be removed in the study eyes and the AcrySof® IOL will be implanted in the capsular bag
Study NCT04658459 — intervention group
Intervention type: PROCEDURE
Intervention: Proximal Interphalangeal Joint Arthroplasty with the Tactys Prosthesis
Study NCT02221232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloraprep
Description: Apply topically.
Study NCT02221232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep
Description: Apply topically.
Study NCT02221232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZuraPrep Vehicle
Description: Apply topically.
Study NCT02701088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracile and Mitomycin-C
Description: All the patients will receive radiochemotherapy with two cycles of 5FU (1,000 mg/m²/d with 96-h infusion, days 1-5 and 29-33 of SIB-IMRT) and Mitomycin-C (10 mg/m², days 1 and 29).
Study NCT02701088 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy
Description: SIB-IMRT schedule of 61.2 Gy/1.7 Gy to the primary tumor, 57.60 Gy / 1.6 Gy to involved nodes, and 54 / 1.5 Gy to elective pelvic lymph nodes.
Study NCT05659433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CEUS-guided percutaneous biopsy
Description: A standard dose of SonoVue ultrasound contrast agent is injected prior to the biopsy, and the percutaneous biopsy is guided in real time, targeting the contrast-enhanced areas of the retroperitoneal tumors (viable, vascularized)
Study NCT05659433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: B-mode US-guided percutaneous biopsy
Description: Standard of care (B-mode) ultrasound-guided percutaneous biopsy, without contrast enhancement
Study NCT00993915 — intervention group
Intervention type: DRUG
Intervention: Atorvastatin
Description: Atorvastatin, 10- 80 mg, once daily, 6 month treatment
Study NCT00760396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-1027
Description: Subjects will
Study NCT02119325 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25% fibre
Description: Test is a powdered beverage with an active component of 25% of fibre (resistant maltodextrin)
Study NCT02119325 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0% fibre
Description: Placebo is an energy matched powdered beverage
Study NCT02279823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-01 solution
Description: Investigational drug solution
Study NCT02279823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil Solution 5%
Description: FDA approved marketed product
Study NCT02279823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Vehicle solution
Study NCT02267356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161
Study NCT02267356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00631189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 5mg oral
Study NCT00631189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: 40mg oral
Study NCT00631189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10mg oral
Study NCT00874770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 3 mg, Daily, 48 weeks
Study NCT00874770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 10 mg, Daily, 48 weeks
Study NCT00874770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, Daily, 48 weeks
Study NCT00874770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablet, oral, 0 mg, Daily 48 weeks
Study NCT00874770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a
Description: Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
Study NCT00874770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alpha-2a
Description: Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
Study NCT00874770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
Study NCT00874770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
Study NCT03575390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
Study NCT03575390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate
Description: Pomegranate extract 500mg
Study NCT01129726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transillumination-guided Fiberoptic Intubation
Description: Light guided, Non-invasive
Study NCT01659372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Study NCT01659372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Study NCT01956656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lotus leaf mouthwash
Description: Saline mouthwash to be used for 4 days twice daily by one group the other group the lotus leaf mouthwash
Study NCT02955576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle HA patch
Description: The microneedle HA patch were made of hyaluronic acid with microneedles which can enhance the drug permeation. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.~Microneedle HA patch (Therapass®, RMD-6.5A) was prepared at Raphas Co., Ltd. (Cheonan, South Korea).~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.
Study NCT02955576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patch
Description: The patch were made of hyaluronic acid with no microneedles to rule out the occlusion effect of microneedle HA patch. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.~The hyaluronic acid patch was prepared at Raphas Co., Ltd. (Cheonan, South Korea) for this clinical trial, not for sale.
Study NCT02955576 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.
Study NCT00973154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: 50mg per day of prednisone orally for 7 days versus placebo
Study NCT00973154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 50mg per day of prednisone orally for 7 days versus placebo
Study NCT04873414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma treatment
Description: Convalescent Plasma collected from patients who recover from COVID-19 and have been discharged from the hospital for at least 14 days.
Study NCT02785497 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: will be turn on the equipment, positioning the patient but no put intensity
Study NCT02785497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment group
Description: This group will receive electrostimulation
Study NCT01569360 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corset
Description: the patients are assigned the use of a custome made corset during daytime
Study NCT03758521 — intervention group
Intervention type: DEVICE
Intervention: Transcranial magnetic stimulation (TMS)
Description: Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
Study NCT03758521 — intervention group
Intervention type: DEVICE
Intervention: Magnetic resonance imaging (MRI)
Description: These will be outpatient MRI studies that are planned without sedation. Subjects enrolled at BCH will undergo brain MRI, including volumetric MRI, MRS, and diffusion tensor imaging (DTI). The data will help define the natural history of brain volume, brain myelination and spectroscopic (e.g. GABA) abnormalities.
Study NCT03758521 — intervention group
Intervention type: DEVICE
Intervention: Electroencephalogram (EEG)
Description: These will be outpatient EEG recordings that span 20-60 minutes and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
Study NCT03758521 — intervention group
Intervention type: PROCEDURE
Intervention: Bio-specimen Collection
Description: Bio-specimen collection will include blood, urine, saliva, hair, stool, and a skin biopsy. Blood, urine, saliva, blood spots, and hair samples will also be banked for to-be-determined (TBD) studies.
Study NCT00588536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
Study NCT00588536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Thioguanine
Description: 6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.
Study NCT00588536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: 5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
Study NCT01047696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plancha
Description: locally developed chimney stove
Study NCT04876534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 20 Mg/mL Intravenous Solution
Description: Intravenous administration
Study NCT04876534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MethylPREDNISolone Injectable Solution
Description: Intravenous administration
Study NCT00725634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-299
Description: AV-299 monotherapy will be given as intravenous infusion in dose-escalation cohorts at 2, 5, 10, and 20 mg/kg. Once the RP2D has been determined the cohort may be expanded to include up to 12 patients for safety assessment and enriched with up to 12 additional Multiple Myeloma patients.
Study NCT00725634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-299 + erlotinib
Description: AV-299 will be given as intravenous infusion at RP2D in combination with erlotinib (150 mg daily). Once the combination-RP2D has been determined the cohort may be expanded to include up to 12 additional patients.
Study NCT04636866 — intervention group
Intervention type: OTHER
Intervention: NO intervention
Description: NO intervention
Study NCT00307528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK513026
Description: Two-dose intramuscular injection. Five different formulations, each administered to one Group
Study NCT00307528 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax 23™
Description: Single dose intramuscular injection.